/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

B

Brigida Anna Maiorano

Vita-Salute San Raffaele University(IT)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

130

Papers

1.0K

Citations

21

h-index

36

i10-index

Brigida Anna Maiorano is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Bladder and Urothelial Cancer Treatments & Renal cell carcinoma treatment. The author has an h-index of 21, co-authored 111 publications.

ORCID: 0000-0001-5423-3158

Research Topics

Cancer Immunotherapy and Biomarkers Bladder and Urothelial Cancer Treatments Renal cell carcinoma treatment PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment

Papers by this author

works

Targeting KRASG12C in colorectal cancer: the beginning of a new era

2022 · ESMO Open · 34 citations

https://doi.org/10.1016/j.esmoop.2022.100745

Davide Ciardiello Brigida Anna Maiorano Erika Martinelli

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis

2022 · ESMO Open · 31 citations

https://doi.org/10.1016/j.esmoop.2022.100575

Brigida Anna Maiorano Ugo De Giorgi Giandomenico Roviello Carlo Messina

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis

2022 · International Journal of Gynecological Cancer · 22 citations

https://doi.org/10.1136/ijgc-2022-003614

Brigida Anna Maiorano Mauro Francesco Pio Maiorano Domenica Lorusso Massimo Di Maïo

Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)

2022 · ESMO Open · 11 citations

https://doi.org/10.1016/j.esmoop.2022.100567

Davide Ciardiello Cinzia Chiarazzo Vincenzo Famiglietti Angela Damato

Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)

2024 · Clinical Genitourinary Cancer · 9 citations

https://doi.org/10.1016/j.clgc.2024.102099

Elisabetta Gambale Marco Maruzzo Carlo Messina Irene De Gennaro Aquino

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study

2024 · Clinical Genitourinary Cancer · 2 citations

https://doi.org/10.1016/j.clgc.2024.102267

Brigida Anna Maiorano Martina Catalano Chiara Mercinelli Giandomenico Roviello

Research topics

topics

Cancer Immunotherapy and Biomarkers

Bladder and Urothelial Cancer Treatments

Renal cell carcinoma treatment

PARP inhibition in cancer therapy

Ovarian cancer diagnosis and treatment

Chat about Author

Papers

Chat

Click to start Chat